JP2024095680A5 - - Google Patents

Download PDF

Info

Publication number
JP2024095680A5
JP2024095680A5 JP2024040767A JP2024040767A JP2024095680A5 JP 2024095680 A5 JP2024095680 A5 JP 2024095680A5 JP 2024040767 A JP2024040767 A JP 2024040767A JP 2024040767 A JP2024040767 A JP 2024040767A JP 2024095680 A5 JP2024095680 A5 JP 2024095680A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
human
human subject
months
brain mass
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024040767A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024095680A (ja
Filing date
Publication date
Priority claimed from JP2021502545A external-priority patent/JP2021531276A/ja
Application filed filed Critical
Publication of JP2024095680A publication Critical patent/JP2024095680A/ja
Publication of JP2024095680A5 publication Critical patent/JP2024095680A5/ja
Pending legal-status Critical Current

Links

JP2024040767A 2018-07-18 2024-03-15 完全ヒトグリコシル化ヒトα-L-イズロニダーゼ(IDUA)を用いたムコ多糖症I型の治療 Pending JP2024095680A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862699923P 2018-07-18 2018-07-18
US62/699,923 2018-07-18
JP2021502545A JP2021531276A (ja) 2018-07-18 2019-07-17 完全ヒトグリコシル化ヒトα−L−イズロニダーゼ(IDUA)を用いたムコ多糖症I型の治療
PCT/US2019/042205 WO2020018665A1 (en) 2018-07-18 2019-07-17 Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idus)

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021502545A Division JP2021531276A (ja) 2018-07-18 2019-07-17 完全ヒトグリコシル化ヒトα−L−イズロニダーゼ(IDUA)を用いたムコ多糖症I型の治療

Publications (2)

Publication Number Publication Date
JP2024095680A JP2024095680A (ja) 2024-07-10
JP2024095680A5 true JP2024095680A5 (cg-RX-API-DMAC7.html) 2024-09-18

Family

ID=69164759

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021502545A Pending JP2021531276A (ja) 2018-07-18 2019-07-17 完全ヒトグリコシル化ヒトα−L−イズロニダーゼ(IDUA)を用いたムコ多糖症I型の治療
JP2024040767A Pending JP2024095680A (ja) 2018-07-18 2024-03-15 完全ヒトグリコシル化ヒトα-L-イズロニダーゼ(IDUA)を用いたムコ多糖症I型の治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021502545A Pending JP2021531276A (ja) 2018-07-18 2019-07-17 完全ヒトグリコシル化ヒトα−L−イズロニダーゼ(IDUA)を用いたムコ多糖症I型の治療

Country Status (10)

Country Link
US (1) US20210275647A1 (cg-RX-API-DMAC7.html)
EP (1) EP3823590A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021531276A (cg-RX-API-DMAC7.html)
KR (1) KR20210034037A (cg-RX-API-DMAC7.html)
AU (1) AU2019306236A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021000830A2 (cg-RX-API-DMAC7.html)
CA (1) CA3106651A1 (cg-RX-API-DMAC7.html)
IL (1) IL280198B2 (cg-RX-API-DMAC7.html)
SG (1) SG11202100423YA (cg-RX-API-DMAC7.html)
WO (1) WO2020018665A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3068328A1 (en) 2017-07-06 2019-01-10 The Trustees Of The University Of Pennsylvania Aav9-mediated gene therapy for treating mucopolysaccharidosis type i
EP3684938A1 (en) 2017-09-22 2020-07-29 The Trustees of the University of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
US20190114858A1 (en) * 2017-10-16 2019-04-18 Raritan Americas, Inc. System for controlling access to an equipment rack and intelligent power distribution unit and control unit used therein

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020095135A1 (en) * 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
CA2486584A1 (en) * 2002-06-07 2003-12-18 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
US8114627B2 (en) * 2006-09-21 2012-02-14 The Scripps Research Institute Genetically programmed expression of selectively sulfated proteins in eubacteria
EP3230438B1 (en) * 2014-12-12 2024-12-04 University of Copenhagen N-glycosylation
KR20220082100A (ko) * 2015-05-15 2022-06-16 리젠츠 오브 더 유니버시티 오브 미네소타 중추 신경계로의 아데노-연관 치료적 전달
MA43968A (fr) * 2016-02-03 2018-12-12 Univ Pennsylvania Thérapie génique pour traiter la mucopolysaccharidose de type i
HRP20231451T1 (hr) * 2016-02-05 2024-03-01 Emory University Ubrizgavanje jednolančanog ili samo-komplementarnog adeno-povezanog virusa 9 u cerebrospinalnu tekućinu
IL309808B2 (en) * 2016-11-15 2025-04-01 Univ Minnesota Method for improving neurological function in MPSI and MPSII and other neurological disorders
JP2020508289A (ja) * 2017-01-31 2020-03-19 レジェンクスバイオ インコーポレーテッド 完全ヒトグリコシル化ヒトα−L−イズロニダーゼ(IDUA)を用いたムコ多糖症I型の治療

Similar Documents

Publication Publication Date Title
JP2024112876A5 (cg-RX-API-DMAC7.html)
CN100389820C (zh) 含肉毒神经毒素的治疗剂
JP2007314575A (ja) 治療剤としてのプロサポシンおよびサイトカイン由来ペプチド
JP2005516949A (ja) Gdnfの骨格筋へのアデノ随伴ウイルス媒介性のデリバリー
CA3134523A1 (en) Compositions useful for treatment of pompe disease
JPH0228199A (ja) ヒト神経成長因子
AU2019304569B2 (en) Treatment of neuropathy with DNA constructs expressing IGF-1 isoforms
CN111954537A (zh) 生长分化因子15融合蛋白
Shiozawa et al. Tyrosine triple mutated AAV2-BDNF gene therapy in an inner retinal injury model induced by intravitreal injection of N–methyl-D-aspartate (NMDA)
US20240002462A1 (en) Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs
JP2020508289A5 (cg-RX-API-DMAC7.html)
US20240261364A1 (en) Peptides and methods of using the same
KR20230003569A (ko) Cdkl5 결핍 장애 (cdd)의 치료에 유용한 조성물
WO2015001352A1 (en) Novel regenerative therapy
JP2024511024A (ja) 21-ヒドロキシラーゼ欠損症の遺伝子治療
US20210207168A1 (en) Aav-compatible laminin-linker polymerization proteins
JP2024540470A5 (cg-RX-API-DMAC7.html)
WO2003082315A1 (fr) Remede contre l'hypermyotonie
US20210130429A1 (en) Recombinant adeno-associated virus-mediated expression of fractalkine for treatment of neuroinflammatory and neurodegenerative diseases
JP2021531276A5 (cg-RX-API-DMAC7.html)
CA3190597A1 (en) Compositions and methods for the treatment of ocular neuroinflammation
CN119497719A (zh) Serpin肽衍生物及其使用方法
HK40121727A (en) Serpin peptide derivatives and methods of using the same
WO2024216080A1 (en) Immunosuppressive regimens and methods thereof
CN118252953A (zh) 一种用于神经退行性疾病治疗的基因序列构建体及其应用